Prof Dame Valerie Beral
| Research Area: | Clinical Epidemiology |
|---|---|
| Scientific Themes: | Clinical Trials & Epidemiology |
| Keywords: | million women study, epic, cancer epidemiology |
| Web Links: |
Valerie studied medicine at Sydney University, Australia. After a few years of clinical work in Australia, New Guinea and the UK, she spent almost 20 years at the London School of Hygiene & Tropical Medicine working in the Department of Epidemiology. In 1988 she became the Director of the Cancer Epidemiology Unit in Oxford. Major focuses of her research include the role of reproductive, hormonal and infectious agents in cancer. She is Principal Investigator for the 'Million Women Study' and leads the international collaborative studies of breast, ovarian and endometrial cancer.
There are no collaborations listed for this principal investigator.
2010. UK cancer survival statistics BRITISH MEDICAL JOURNAL, 341 (7768), pp. 309-309. | Read more
2010. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet, 375 (9732), pp. 2143-2151. Read abstract | Read more
Information is scarce about the combined effects on breast cancer incidence of low-penetrance genetic susceptibility polymorphisms and environmental factors (reproductive, behavioural, and anthropometric risk factors for breast cancer). To test for evidence of gene-environment interactions, we compared genotypic relative risks for breast cancer across the other risk factors in a large UK prospective study. Hide abstract
2009. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst, 101 (5), pp. 296-305. Read abstract | Read more
With the exception of breast cancer, little is known about the effect of moderate intakes of alcohol, or of particular types of alcohol, on cancer risk in women. Hide abstract
2009. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ, 339 pp. b4583. Read abstract
To examine the duration and magnitude of increased risk of venous thromboembolism after different types of surgery. Hide abstract
2008. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371 (9609), pp. 303-314. Read abstract | Read more
Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Hide abstract
2007. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet, 370 (9599), pp. 1609-1621. Read abstract | Read more
Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use. Hide abstract
2007. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet, 369 (9574), pp. 1703-1710. Read abstract | Read more
Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 developing the malignancy and 4600 dying from it every year. However, there is limited information about the risk of ovarian cancer associated with the use of hormone replacement therapy (HRT). Hide abstract
2005. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet, 365 (9470), pp. 1543-1551. Read abstract | Read more
Postmenopausal women who use hormone-replacement therapy (HRT) containing oestrogen alone are at increased risk of endometrial cancer. To minimise this risk, many HRT users who have not had a hysterectomy use combined oestrogen-progestagen preparations or tibolone. Limited information is available on the incidence of endometrial cancer in users of these therapies. Hide abstract
2004. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries. Lancet, 363 (9414), pp. 1007-1016. Read abstract | Read more
The Collaborative Group on Hormonal Factors in Breast Cancer has brought together the worldwide epidemiological evidence on the possible relation between breast cancer and previous spontaneous and induced abortions. Hide abstract
Risk factors for ovarian cancer by histological phenotype in the Million Women Study
This project is to investigate how a range of different factors affect a woman’s risk of developing ovarian cancer. The primary aim of the project is to examine the association between various lifestyle factors and incident ovarian cancers among 1.3 million middle-aged women recruited into the Million Women Study, and to investigate whether these associations vary depending on the histological phenotype of the tumour. A secondary aim is to explore genetic risk factors for ovarian cancer, ...
Role of screening and other factors on cervical cancer incidence in a large cohort of women
This project is to investigate how women’s screening history and their behaviours interact in affecting their risk of developing cervical cancer. Part of the project will involve examining risk factors for incident cervical cancers among 1.3 million middle aged women recruited into the Million Women Study. Detailed screening histories, pathology reports and archival cervical smears slides are available for a subgroup of the cohort. As well, there are opportunities to work with collaborators, ...
Newt
Pinfox